New One Minute Rapid-Acting Insulin: Lyumjev
Jul 25, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Brianna Belton, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences
Lyumjev, recently approved by the FDA, reaches the bloodstream only one minute after injection; how does its performance compare to Humalog?
The FDA has just approved the new rapid-acting insulin Lyumjev, also known as insulin lispro-aabc, injection that comes in 100 units/mL and 200 units/mL. It is indicated to improve glycemic control in adults with type 1 and type 2 diabetes. In phase 3, 26-week clinical trials, PRONTO-T1D and PRONTO-T2D, Lyumjev and Humalog (insulin lispro injection) were compared both in combination with either insulin glargine or insulin degludec in patients with type 1 (PRONTO-T1D) and type 2 diabetes (PRONTO-T2D)....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.